Sarepta Therapeutics（SRPT）今日盘前大跌31.76%，引发市场广泛关注。该公司股价暴跌主要源于其基因疗法临床试验中出现第二例死亡病例的消息。
据悉，Sarepta Therapeutics披露了其用于治疗一种罕见肌肉萎缩症的基因疗法试验中出现第二例死亡病例。这是继3月份报告第一例死亡病例后的又一打击。肝损伤被认为是Elevidys和其他使用腺相关病毒载体注入修饰基因的基因疗法的一个已知风险。这一消息严重打击了投资者信心，导致公司股价大幅下挫。
为应对这一情况，Sarepta Therapeutics已采取紧急措施。公司宣布暂停向无法行走的患者运送治疗药物，并已通知全球卫生机构和美国食品及药物管理局（FDA）。与此同时，多家券商也对Sarepta的股票评级做出调整。Piper Sandler将其评级从"增持"下调至"中性"，目标价从70.00美元大幅下调至36.00美元。BMO资本市场也将评级下调至"持有"，目标价从120美元下调至70美元。如果这一跌势持续，Sarepta将可能损失近三分之一的市值，对公司未来发展造成重大影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.